Mitoquinone BPH Treatment Inhibiting AR and NLRP3 Pathways

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for benign prostatic hyperplasia (BPH) often have side effects and are not as effective as desired, particularly those involving synthetic chemicals, necessitating a safer and more effective natural alternative.

Innovation Solution

A pharmaceutical composition and health functional food containing mitoquinone, which inhibits the androgen receptor (AR) and nucleotide oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways to suppress dihydrotestosterone-induced prostate cell proliferation and oxidative stress.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If synthetic chemical treatments are used for BPH, then treatment effectiveness is improved, but side effects increase and safety decreases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter from synthetic chemicals to natural compounds (mitoquinone and curcumin), maintaining therapeutic effectiveness while eliminating harmful side effects. The composition uses naturally derived substances that target the same pathological pathways (AR and NLRP3) without the toxicity of synthetic alternatives.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple natural compounds (mitoquinone and curcumin) in a composite formulation to achieve synergistic effects. This composite approach enhances treatment effectiveness while maintaining the safety profile of natural substances, resolving the contradiction between efficacy and safety.

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If natural substances are used instead of synthetic chemicals, then safety is improved, but treatment effectiveness may decrease

Engineering Contradiction:

ImprovesafetyVSAvoidtreatment effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent optimizes the concentration and formulation parameters of natural compounds to ensure therapeutic effectiveness. Mitoquinone and curcumin are used at specific concentrations that maximize their ability to inhibit AR and NLRP3 pathways while maintaining safety, proving that natural substances can be as effective as synthetic ones when properly formulated.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

By creating a composite of mitoquinone and curcumin, the patent enhances the overall therapeutic effect beyond what either compound could achieve alone. This synergistic combination ensures that natural substances maintain high treatment effectiveness while preserving safety advantages.

Inventive Principle:

Principle #40Composite materials

3Duration of action of stationary object

If mitoquinone is used to inhibit prostate cell proliferation, then BPH progression is slowed, but the mechanism complexity increases

Engineering Contradiction:

Improvedisease progression controlVSAvoidmechanism complexity

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The patent extracts and targets specific key pathways (AR and NLRP3) that drive BPH progression, rather than attempting to modulate all cellular processes. By focusing on these two critical pathways, the treatment achieves durable disease control through a manageable mechanism that blocks androgen signaling and reduces oxidative stress-driven proliferation.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Mitoquinone effectively inhibits prostate cell proliferation and reduces oxidative stress, thereby alleviating symptoms and progression of BPH, as demonstrated in both cellular and animal models.

Implementation Method 1

Mitoquinone has been shown to inhibit androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways

Methodology Applied

Scientific EffectHormone receptor signaling inhibition:

Implementation Method 2

Mitoquinone has been shown to inhibit androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways

Methodology Applied

Scientific EffectInflammasome pathway inhibition:

Data Source

PatentUS20250205253A1Pharmaceutical composition for preventing or treating benign prostatic hyperplasia

Publication Date: 2025.06.26 UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

AI summary

Provided are a pharmaceutical composition, a health functional food, and a method for preventing or treating benign prostatic hyperplasia (BPH). The present invention includes mitoquinone as an active ingredient and inhibits the androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways to alleviate pathological prostatic hypertrophy and exhibit anti-proliferative and antioxidant effects. Therefore, it can be effectively used in preventing, treating, or ameliorating BPH.